Full Press Release Details
Quanterix Provides Operational and Preliminary
Financial Highlights
Expects Q4 2021 revenue of $29-31 million;
Full year 2021 revenue of $109-111 million
Q4 Product & Service revenue of $28-30
million, 35% growth; Full year 2021 Product & Service revenue of
$104-106 million, 53% growth
Q4 Product (consumables and instruments) revenue
of $21-23 million, 45% growth; Full year 2021
Product revenue of $80-82 million, 84% growth
Company to present at J.P. Morgan Healthcare
Mass. - Jan. 13, 2022 - Quanterix Corporation (NASDAQ: QTRX), a
company digitizing biomarker analysis with the goal of advancing the science of precision health, today provided operational and
preliminary financial highlights for the fourth quarter and fiscal year ending December 31, 2021.
industry will reach its next inflection point in 2022 requiring novel solutions to combat COVID-19 and its new variants like Omicron,
in addition to treating challenging neurodegenerative disorders, including Alzheimer's and Parkinson's which affect more than
7 million people in the United States alone," said Kevin Hrusovsky, Chairman and Chief Executive Officer, Quanterix. "Our
ultra-sensitive biomarker detection technology has been making unprecedented progress in these key therapeutic areas, particularly with
the recent breakthrough device designation for our plasma pTau181 Alzheimer's test and COVID-19 antigen EUA label expansion for
asymptomatic and saliva testing. Quanterix continues to empower drug developers with tests that improve drug trial efficiency, and which
also show promise to payors for early disease detection, treatment for improved outcomes, and cost-effective patient monitoring to deliver
clinical evidence in support of coverage decisions. We believe that the high sensitivity and accuracy of these tests ultimately
have the potential to transform reactive, symptomatic medicine, or "sick-care," to proactive, asymptomatic healthcare."
2021 Operational Highlights
Preliminary Non-Audited Financial
The estimated unaudited financial
results as of and for the fourth quarter and full fiscal year ended December 31, 2021 presented above are preliminary and are
subject to completion of our quarter-end and year-end closing procedures and further financial review. This preliminary financial information
has not been audited by our independent auditing firm. Our actual results may differ from these estimates as a result of the completion
of our quarter-end and year-end closing procedures, review adjustments and other developments that may arise between now and the time
our financial results for the fourth quarter and year are finalized.
at JP Morgan Healthcare Conference
previously announced, Hrusovsky will be presenting the Company's growth and vision for the sixth consecutive year at the
40th Annual J.P. Morgan Healthcare Conference. Hrusovsky's session will take place on Thursday, Jan. 13, 2022,
at 8:15 a.m., EST (5:15 a.m., PST) and will be made available to attendees and the general public. In addition to Hrusovsky's session,
he will also be hosting one-on-one meetings with institutional investors during the conference.
access the live webcast of Quanterix' presentation, please visit: https://jpmorgan.metameetings.net/events/healthcare22/sessions/39930-quanterix-corporation/webcast?gpu_only=true&kiosk=true
is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's
digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability
to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection,
better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come.
The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology,
inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information,
please visit https://www.quanterix.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will,"
"expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.
Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix'
actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix'
filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except
as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change
in expectations, even as new information becomes available.
Paige Romine, 321-652-8370
Investor Relations Contact: